DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of ListingItem 3.01 – Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard;Transfer of Listing.
On November 14, 2017, Diffusion Pharmaceuticals Inc. (the “Company”) received a written notice from the staff of the Listing Qualifications Department of the NASDAQ Stock Market LLC (“NASDAQ”) indicating that the Company has regained compliance with NASDAQ Listing Rule 5550(b)(1) based on the Company’s stockholders’ equity as of September 30, 2017, as reported in the Company’s Quarterly Report on Form 10-Q for the period then ended. The notification stated that the matter of the deficiency, which the Company previously reported on May 26, 2017, is now closed.
About DIFFUSION PHARMACEUTICALS INC. (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc., formerly RestorGenex Corporation, is a clinical-stage biotechnology company. The Company is focused on developing standard-of-care treatments, including radiation therapy and chemotherapy. The Company’s lead product candidate, transcrocetinate sodium, also known as trans sodium crocetinate (TSC) is used in various cancer types, in which tumor oxygen deprivation (hypoxia) is known to diminish the effectiveness of treatments. The Company’s Diffusion’s technology is targeted at overcoming treatment-resistance in solid cancerous tumors by combining its lead product candidate, TSC, with standard-of-care radiation and chemotherapy regimens, thus effecting a better patient survival outcome without the addition of harmful side effects. Its clinical development plan targets TSC at the radiation and chemotherapy sensitization of hypoxic tumor types, with an initial focus on primary brain cancer (glioblastoma or GBM), pancreatic cancer, and brain metastases.
